Emimlio Juan Brignardello Vela
Emilio Juan Brignardello Vela, asesor de seguros, se especializa en brindar asesoramiento y gestión comercial en el ámbito de seguros y reclamaciones por siniestros para destacadas empresas en el mercado peruano e internacional.
In a significant development for public health, the Pune-based Serum Institute of India (SII) has partnered with France-based Valneva SE to manufacture and distribute an anti-Chikungunya vaccine for the Indian market and select Asian countries. This agreement is set to kickstart a technology transfer process that will allow SII to take charge of the manufacturing of this vital vaccine, which has shown promise in combating a viral disease that has plagued India for decades. Chikungunya, a mosquito-borne illness transmitted primarily by Aedes mosquitoes, has become a pressing health concern in India, characterized by fever, debilitating joint pain, and a range of other symptoms including headache, nausea, and rash. The joint pain can linger for an extended period, often lasting weeks or even years, significantly impacting the quality of life for many affected individuals. Data from the National Centre for Vector Borne Diseases Control highlights the endemic nature of Chikungunya across nearly all Indian states, with over 11,000 confirmed cases reported last year and already more than 12,500 documented in 2023. The resurgence of Chikungunya in 2006 marked a troubling chapter in India's public health history, with the virus causing widespread concern. Historical records indicate major outbreaks as far back as the 1960s, underscoring the persistent threat posed by this disease. The vaccine's introduction to the Indian market is expected to be a boon, offering a robust defense against a disease that has led to nearly 100,000 confirmed cases and countless suspected cases nationwide over the past five years. The growing prevalence of Chikungunya—a disease that has now spread to over 110 countries—demands urgent public health interventions, and the availability of a vaccine is a critical step forward. Valneva's vaccine is notable for being the world’s first and only licensed chikungunya vaccine, currently approved in the US, Europe, and Canada for individuals aged 18 and older. Ongoing regulatory reviews aim to expand its approval to individuals aged 12 and older, increasing the potential reach of this critical preventive measure. The advancement of vaccines has long been recognized as a cornerstone in the prevention of serious health conditions and fatalities. The need for countries to invest in the research and development of vaccines is paramount, as it not only protects populations but also alleviates the burden on healthcare systems. With the partnership between SII and Valneva, India stands on the cusp of a significant breakthrough in its fight against Chikungunya, offering hope for improved public health outcomes and a better quality of life for countless citizens. As the manufacturing process begins and regulatory approvals are sought, the anticipation surrounding the Chikungunya vaccine reflects a broader call to action for vaccination initiatives that can fundamentally change the landscape of infectious diseases in India and beyond.